Cargando…
A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer
Macrophages as components of the innate immune system play a critical role in antitumor responses. Strategies for targeting CD47 are becoming a hot spot for cancer therapy. The expression of CD47 is exercised by macrophages to make a distinction between “self” or “nonself.” Anti-CD47 antibodies bloc...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813985/ https://www.ncbi.nlm.nih.gov/pubmed/33469516 http://dx.doi.org/10.3389/fonc.2020.615534 |
_version_ | 1783637962651598848 |
---|---|
author | Lin, Fangzhen Xiong, Mengshang Hao, Wei Song, Yuewen Liu, Ruoqi Yang, Yuanyuan Yuan, Xiangfei Fan, Dongmei Zhang, Yizi Hao, Mu Ye, Zhou Lu, Yang Zhang, Yanjun Wang, Jianxiang Xiong, Dongsheng |
author_facet | Lin, Fangzhen Xiong, Mengshang Hao, Wei Song, Yuewen Liu, Ruoqi Yang, Yuanyuan Yuan, Xiangfei Fan, Dongmei Zhang, Yizi Hao, Mu Ye, Zhou Lu, Yang Zhang, Yanjun Wang, Jianxiang Xiong, Dongsheng |
author_sort | Lin, Fangzhen |
collection | PubMed |
description | Macrophages as components of the innate immune system play a critical role in antitumor responses. Strategies for targeting CD47 are becoming a hot spot for cancer therapy. The expression of CD47 is exercised by macrophages to make a distinction between “self” or “nonself.” Anti-CD47 antibodies block the interaction between macrophage signal regulatory protein-α (SIRPα) and tumor surface CD47. In this study, we report and assess a novel anti-CD47 blocking antibody named 2C8, which exhibits high affinity and tremendous anticancer effects. More concretely, 2C8 significantly induces macrophages, including protumorigenic subtype M2 macrophages killing tumor cells in vitro, and is revealed to be more effective than commercially available anti-CD47 mAb B6H12.2. In vivo, 2C8 controls tumor growth and extends survival of xenograft mice. The antitumor ability of 2C8 might be applicable to many other cancers. The generation of a novel CD47 antibody contributes to consolidating clinical interest in targeting macrophages for the treatment of malignancy and, moreover, as a supplement therapy when patients are resistant or refractory to other checkpoint therapies or relapse after such treatments. |
format | Online Article Text |
id | pubmed-7813985 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78139852021-01-18 A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer Lin, Fangzhen Xiong, Mengshang Hao, Wei Song, Yuewen Liu, Ruoqi Yang, Yuanyuan Yuan, Xiangfei Fan, Dongmei Zhang, Yizi Hao, Mu Ye, Zhou Lu, Yang Zhang, Yanjun Wang, Jianxiang Xiong, Dongsheng Front Oncol Oncology Macrophages as components of the innate immune system play a critical role in antitumor responses. Strategies for targeting CD47 are becoming a hot spot for cancer therapy. The expression of CD47 is exercised by macrophages to make a distinction between “self” or “nonself.” Anti-CD47 antibodies block the interaction between macrophage signal regulatory protein-α (SIRPα) and tumor surface CD47. In this study, we report and assess a novel anti-CD47 blocking antibody named 2C8, which exhibits high affinity and tremendous anticancer effects. More concretely, 2C8 significantly induces macrophages, including protumorigenic subtype M2 macrophages killing tumor cells in vitro, and is revealed to be more effective than commercially available anti-CD47 mAb B6H12.2. In vivo, 2C8 controls tumor growth and extends survival of xenograft mice. The antitumor ability of 2C8 might be applicable to many other cancers. The generation of a novel CD47 antibody contributes to consolidating clinical interest in targeting macrophages for the treatment of malignancy and, moreover, as a supplement therapy when patients are resistant or refractory to other checkpoint therapies or relapse after such treatments. Frontiers Media S.A. 2021-01-05 /pmc/articles/PMC7813985/ /pubmed/33469516 http://dx.doi.org/10.3389/fonc.2020.615534 Text en Copyright © 2021 Lin, Xiong, Hao, Song, Liu, Yang, Yuan, Fan, Zhang, Hao, Ye, Lu, Zhang, Wang and Xiong http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Lin, Fangzhen Xiong, Mengshang Hao, Wei Song, Yuewen Liu, Ruoqi Yang, Yuanyuan Yuan, Xiangfei Fan, Dongmei Zhang, Yizi Hao, Mu Ye, Zhou Lu, Yang Zhang, Yanjun Wang, Jianxiang Xiong, Dongsheng A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer |
title | A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer |
title_full | A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer |
title_fullStr | A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer |
title_full_unstemmed | A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer |
title_short | A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer |
title_sort | novel blockade cd47 antibody with therapeutic potential for cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813985/ https://www.ncbi.nlm.nih.gov/pubmed/33469516 http://dx.doi.org/10.3389/fonc.2020.615534 |
work_keys_str_mv | AT linfangzhen anovelblockadecd47antibodywiththerapeuticpotentialforcancer AT xiongmengshang anovelblockadecd47antibodywiththerapeuticpotentialforcancer AT haowei anovelblockadecd47antibodywiththerapeuticpotentialforcancer AT songyuewen anovelblockadecd47antibodywiththerapeuticpotentialforcancer AT liuruoqi anovelblockadecd47antibodywiththerapeuticpotentialforcancer AT yangyuanyuan anovelblockadecd47antibodywiththerapeuticpotentialforcancer AT yuanxiangfei anovelblockadecd47antibodywiththerapeuticpotentialforcancer AT fandongmei anovelblockadecd47antibodywiththerapeuticpotentialforcancer AT zhangyizi anovelblockadecd47antibodywiththerapeuticpotentialforcancer AT haomu anovelblockadecd47antibodywiththerapeuticpotentialforcancer AT yezhou anovelblockadecd47antibodywiththerapeuticpotentialforcancer AT luyang anovelblockadecd47antibodywiththerapeuticpotentialforcancer AT zhangyanjun anovelblockadecd47antibodywiththerapeuticpotentialforcancer AT wangjianxiang anovelblockadecd47antibodywiththerapeuticpotentialforcancer AT xiongdongsheng anovelblockadecd47antibodywiththerapeuticpotentialforcancer AT linfangzhen novelblockadecd47antibodywiththerapeuticpotentialforcancer AT xiongmengshang novelblockadecd47antibodywiththerapeuticpotentialforcancer AT haowei novelblockadecd47antibodywiththerapeuticpotentialforcancer AT songyuewen novelblockadecd47antibodywiththerapeuticpotentialforcancer AT liuruoqi novelblockadecd47antibodywiththerapeuticpotentialforcancer AT yangyuanyuan novelblockadecd47antibodywiththerapeuticpotentialforcancer AT yuanxiangfei novelblockadecd47antibodywiththerapeuticpotentialforcancer AT fandongmei novelblockadecd47antibodywiththerapeuticpotentialforcancer AT zhangyizi novelblockadecd47antibodywiththerapeuticpotentialforcancer AT haomu novelblockadecd47antibodywiththerapeuticpotentialforcancer AT yezhou novelblockadecd47antibodywiththerapeuticpotentialforcancer AT luyang novelblockadecd47antibodywiththerapeuticpotentialforcancer AT zhangyanjun novelblockadecd47antibodywiththerapeuticpotentialforcancer AT wangjianxiang novelblockadecd47antibodywiththerapeuticpotentialforcancer AT xiongdongsheng novelblockadecd47antibodywiththerapeuticpotentialforcancer |